Comparison
Tirzepatide Versus Liraglutide
Liraglutide is an older, daily GLP-1 receptor agonist; tirzepatide is a weekly dual GIP/GLP-1 agonist. No head-to-head randomised trial of the two for weight management is cited here, so any comparison rests on cross-trial inference, which is weak. What is documented is that liraglutide's trial weight reductions were substantially smaller and it requires daily injection.
Key takeaways
- Liraglutide is dosed daily; tirzepatide weekly.
- Liraglutide acts on GLP-1 alone; tirzepatide on both GIP and GLP-1 receptors.
- No head-to-head trial for weight management is cited on this site.
- Cross-trial comparison is weak evidence and is labelled as such here.
- Liraglutide has longer post-marketing history and generic availability in some markets.
| Liraglutide dosing | Daily subcutaneous injection |
|---|---|
| Tirzepatide dosing | Weekly subcutaneous injection |
| Mechanism | GLP-1 alone vs dual GIP/GLP-1 |
| Head-to-head trial | None cited here |
| Comparison basis | Cross-trial inference only — weak evidence |
Can these two drugs be compared fairly?
Not with confidence. A fair comparison requires randomising the same population to both, which is what SURMOUNT-5 did for tirzepatide and semaglutide. No equivalent trial is cited here for liraglutide, so any statement that one is more effective rests on placing separate trials side by side — different populations, eras, and protocols.
What can be said without inference is structural: dosing frequency differs, mechanism differs, and liraglutide has a longer post-marketing record.
When might a daily GLP-1 still be preferred?
Availability, cost, and coverage frequently decide this in practice rather than efficacy. Liraglutide has generic availability in some markets, which can make it substantially cheaper, and some prescribers prefer the shorter half-life when a rapid ability to stop matters — for example when tolerability is uncertain.
What the evidence shows
- Structural differences in dosing frequency and receptor targets.
- Longer post-marketing history for liraglutide.
What the evidence does not show
- A reliable head-to-head efficacy comparison — no such trial is cited here.
- That cross-trial figures support a superiority claim.
Related: Versus semaglutide
How large is the effect across the verified trials?
| Trial arm | Point estimate | Range | N |
|---|---|---|---|
| SURMOUNT-1 · 15 mg | 20.9% | 19.5% to 22.3% | 2,539 |
| SURMOUNT-1 · 10 mg | 19.5% | 18.2% to 20.8% | 2,539 |
| SURMOUNT-1 · 5 mg | 15.0% | 13.8% to 16.2% | 2,539 |
| SURMOUNT-2 · 15 mg | 14.7% | 13.4% to 16.0% | 938 |
| SURMOUNT-2 · 10 mg | 12.8% | 11.5% to 14.1% | 938 |
| SURMOUNT-1 · placebo | 3.1% | 2.3% to 3.9% | 2,539 |
| Series | Wk 0 | Wk 12 | Wk 24 | Wk 40 | Wk 56 | Wk 72 |
|---|---|---|---|---|---|---|
| Tirzepatide 15 mg | 0% | -6.5% | -12.4% | -16.8% | -19.3% | -20.9% |
| Tirzepatide 5 mg | 0% | -5.1% | -9.3% | -12.4% | -14.2% | -15.0% |
| Placebo | 0% | -1.4% | -2.3% | -2.8% | -3.0% | -3.1% |
When was each piece of this evidence established?
| Date | Event |
|---|---|
| May 2022 | Tirzepatide approved as Mounjaro for type 2 diabetes |
| Jun 2022 | SURMOUNT-1 published in the New England Journal of Medicine |
| Jul 2023 | SURMOUNT-2 published in the Lancet |
| Nov 2023 | Tirzepatide approved as Zepbound for chronic weight management |
| Dec 2023 | SURMOUNT-4 withdrawal results published in JAMA |
| Jun 2024 | SURMOUNT-OSA published; obstructive sleep apnoea evidence established |
| May 2025 | SURMOUNT-5 head-to-head against semaglutide published in NEJM |
What can be said without a head-to-head trial?
Structural facts, and not much more. Liraglutide is dosed daily and acts on the GLP-1 receptor alone; tirzepatide is weekly and acts on both GIP and GLP-1 receptors. Liraglutide has a longer post-marketing record and generic availability in some markets, which can make it substantially cheaper.
What cannot be said responsibly is which produces more weight loss, because establishing that requires randomising the same population to both — which is what SURMOUNT-5 did for semaglutide and what no trial cited here has done for liraglutide.
When is the older drug the better choice?
When cost or availability decides it, which in practice is often. Generic availability changes the financial picture materially, and a cheaper drug a person can sustain outperforms a more effective drug they stop paying for. Some prescribers also prefer a shorter half-life where the ability to stop quickly matters — during a tolerability trial, or ahead of a planned procedure.
Framing drug choice purely as an efficacy ranking misses that adherence and affordability are themselves determinants of outcome.
What does this page cover, and what does it deliberately leave out?
This page addresses Mechanism, use, evidence, administration and safety and cost, organised around the primary question of tirzepatide vs liraglutide. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Mechanism | Covered on this page | Primary evidence |
| Use | Covered on this page | Primary evidence |
| Evidence | Covered on this page | Primary evidence |
| Administration | Covered on this page | Primary evidence |
| Safety and cost | Covered on this page | Primary evidence |
| Individualized clinical instruction | Deliberately not covered | Belongs with a prescriber who knows your history |
What are the limits of what this page can tell you?
Every page on this site rests on a specific clinical evidence, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for a prescriber who knows your history.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
This page would be revised, with the change recorded in its history, if any of the following occurred:
- New primary evidence bearing directly on tirzepatide vs liraglutide.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
What do the technical terms on this page mean?
Definitions for the 6 technical terms this page uses, including GIP, GLP-1, adherence, half-life — in the specific sense used above.
| GIP | Glucose-dependent insulinotropic polypeptide. An incretin hormone released by the small intestine after eating. Tirzepatide activates its receptor alongside the GLP-1 receptor, which is the feature that distinguishes it from single-agonist drugs such as semaglutide. |
|---|---|
| GLP-1 | Glucagon-like peptide-1. An incretin hormone that slows gastric emptying, signals satiety to the brain, stimulates glucose-dependent insulin release, and suppresses inappropriate glucagon secretion. |
| adherence | The extent to which a person takes a medicine as prescribed. Real-world adherence to incretin therapy is considerably lower than in trials, which is a principal reason real-world weight outcomes are smaller. |
| half-life | The time taken for the amount of drug in the body to fall by half. Tirzepatide's is roughly five days, which supports once-weekly dosing and means steady state takes several weeks. |
| placebo | An inactive comparator given so that the effect of the drug can be separated from the effect of being in a trial. Placebo groups in the SURMOUNT trials still lost some weight, which is why the placebo-subtracted difference matters more than the raw figure. |
| subcutaneous | Beneath the skin. Tirzepatide is given by subcutaneous injection, usually into the abdomen, thigh, or upper arm. |
Frequently asked questions
Is tirzepatide better than liraglutide?
No head-to-head trial is cited here, so a reliable comparison cannot be made from this site's evidence.
How does dosing differ?
Liraglutide is daily; tirzepatide is weekly.
Is liraglutide cheaper?
It has generic availability in some markets, which can lower cost. Verify current pricing locally.
Do they work the same way?
No. Liraglutide acts on GLP-1 alone; tirzepatide acts on both GIP and GLP-1 receptors.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.